Background COPD patients have high pulmonary and systemic oxidative stress that
correlates with severity of disease. Sulforaphane has been shown to induce expression of
antioxidant genes via activation of a transcription factor, nuclear factor erythroid-2 related
factor 2 (Nrf2). Methods This parallel, placebo-controlled, phase 2, randomized trial was
conducted at three US academic medical centers. Patients who met GOLD criteria for COPD
and were able to tolerate bronchoscopies were randomly assigned (1: 1: 1) to receive …

Correction: Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD:
A Randomized, Double-Blind, Placebo C … Correction: Lack of Effect of Oral Sulforaphane
Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo
Controlled Trial … (2016) Lack of Effect of Oral Sulforaphane Administration on Nrf2
Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial. PLoS ONE 11(11):
e0163716. doi:10.1371/journal.pone.0163716 …